Pamela Sutton-Wallace
About Pamela Sutton-Wallace
Pamela Sutton-Wallace (age 55) is an independent director of Consensus Cloud Solutions (CCSI) since October 2021. She serves on the Audit Committee and chairs the Environmental, Social and Corporate Governance (ESG) Committee. She is President of Yale-New Haven Health (since February 2024) and holds a BA in Political Science and African-American Studies from Washington University in St. Louis and an MPH from Yale University .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Yale-New Haven Health | President | Feb 2024–present | Health system leadership |
| Yale-New Haven Health | Chief Operating Officer | Jul 2022–Feb 2024 | Operations oversight |
| New York-Presbyterian | President | May 2021–Jul 2022 | Hospital/health system leadership |
| New York-Presbyterian | SVP & Regional COO | Nov 2019–Apr 2021 | Regional operations |
| UVA Medical Center | Chief Executive Officer | 2014–2019 | Academic medical center CEO |
| Duke University Health System | Multiple leadership roles incl. SVP Hospital Operations | ~17 years | Hospital operations leadership |
| Pfizer; Blue Cross & Blue Shield of North Carolina | Various roles | Prior to Duke/UVA | Pharma and insurance experience |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| J2 Global (Ziff Davis predecessor) | Director | Oct 2020–Oct 2021 | Appointed; no related-party transactions under Item 404(a) disclosed |
Board Governance
- Independence: Determined independent under Nasdaq rules; only CEO Scott Turicchi is non-independent .
- Committee assignments: Audit Committee member; ESG Committee Chair (across 2022–2025) .
- Governance practices: Independent chair, supermajority independent board, majority vote standard, hedging/pledging prohibited, robust overboarding policies, annual self-evaluations .
| Governance Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Independence | Independent | Independent | Independent | Independent |
| Audit Committee | Member | Member | Member | Member |
| ESG Committee | Chair | Chair | Chair | Chair |
Fixed Compensation
| Component | Amount | Notes |
|---|---|---|
| Annual Cash Retainer (Non-Employee Director) | $70,000 | Initial director program (post-spin) |
| Annual Equity Retainer (RSUs) | $200,000 | Time-based RSUs for directors |
| Lead Independent Director Retainer | $15,000 (cash) | If applicable |
| Audit Committee Chair | $25,000 (cash) | Committee chair fee |
| Compensation Committee Chair | $15,000 (cash) | Committee chair fee |
| ESG Committee Chair | $15,000 (cash) | Committee chair fee |
CCSI’s corporate governance highlights also prohibit hedging/pledging, reinforcing alignment with shareholders .
Performance Compensation
| Element | Structure | Performance Metrics |
|---|---|---|
| Director equity | Time-based RSUs | No performance metrics disclosed for director pay (time-based vesting) |
Other Directorships & Interlocks
| Company | Role | Period | Interlock/Conflict Notes |
|---|---|---|---|
| J2 Global, Inc. (NASDAQ: ZD) | Director | Oct 2020–Oct 2021 | Appointed; Item 404(a) related-party transactions: none; served on Compensation and Corporate Governance & Nominating Committees |
| Current other public boards | None | — | CCSI proxy lists none |
Expertise & Qualifications
- 27+ years in healthcare system leadership; CEO/COO roles across leading institutions; operations expertise .
- Education: BA (Washington University), MPH (Yale University) .
- Board contributions: ESG oversight; healthcare operations perspective to a health-data company .
Equity Ownership
| Holder | Shares Beneficially Owned | Date/Source |
|---|---|---|
| Pamela Sutton-Wallace | 11,407 | As of April 18, 2023 (CCSI DEF 14A) |
| Pamela Sutton-Wallace | 952 | Pre-spin expected ownership (Sept 9, 2021) |
- Hedging/pledging of company stock prohibited by policy .
Say-on-Pay and Shareholder Voting Signals
| Meeting Date | Proposal | For | Against | Abstain | Broker Non-Votes |
|---|---|---|---|---|---|
| Jun 12, 2024 | Elect Directors (Class III): Pamela Sutton-Wallace | 13,307,026 | 552,218 | 9,734 | 1,249,975 |
| Jun 12, 2024 | Ratify Auditor (Deloitte 2024) | 15,054,279 | 24,235 | 40,439 | 0 |
| Jun 12, 2024 | Say-on-Pay (NEO compensation) | 13,249,516 | 604,496 | 14,966 | 1,249,975 |
| Jun 11, 2025 | Say-on-Pay (NEO compensation) | 15,526,874 | 763,634 | 20,918 | 1,078,935 |
Her 2024 director election received 13.31M “For” votes vs. 0.55M “Against,” indicating strong investor support .
Potential Conflicts & Related-Party Exposure
- CCSI independence review found no relationships that impair independence for Sutton-Wallace .
- Prior J2 Global appointment disclosed no reportable related-party transactions under Item 404(a) .
Governance Assessment
- Strengths: Independent director; ESG Committee Chair; consistent Audit Committee service; strong healthcare operations background relevant to CCSI’s health-data business; robust policies (hedging/pledging prohibited; overboarding limits); repeated positive shareholder voting outcomes on governance items .
- Alignment: Holds company equity; director comp includes material RSU component; no hedging/pledging; no related-party issues identified .
- Risks/Red Flags: None disclosed regarding attendance, pledging, related party transactions, or say-on-pay backlash; “OTHER PUBLIC COMPANY BOARDS: None” limits interlock risks .